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Background: Tumor volume has been shown to be a prognostic
factor for the response of some tumors to radiotherapy. TNM stage
has prognostic value for patients treated surgically for non-small cell
lung cancer (NSCLC), but its value is less clear for patients treated
by nonsurgical means. This may be because tumor size is not a
consistent determinant of T stage or stage group. As part of the
preliminary analyses for the Trans-Tasman Radiation Oncology
Group 99-05 study, the authors performed this analysis to determine
to what extent stage reflects tumor volume.
Methods: In this prospective multicenter observational study, pa-
tients had to have histologically proven NSCLC, no evidence of
disease beyond the primary site or thoracic lymph nodes, and been
planned for radical radiotherapy with or without chemotherapy.
Tumor volume measurements were based on computed tomography-
based treatment planning images.
Results: Four hundred four patients were available for analysis.
There was a strong correlation between (log) maximum tumor
diameter and (log) tumor volume (r  0.93, p  0.001). Although
there was a highly significant trend of increasing volume with
increasing T stage and stage group, when tumors were categorized
into four groups according to increasing volume, there was only
55% concordance with T stage and 67% concordance with stage
group.
Conclusions: There is limited correlation between tumor size and
disease stage in patients with NSCLC. This justifies documentation
and investigation of size as a potential prognostic factor independent
of stage. Maximum tumor diameter may be an adequate substitute
for volume as a measurement of size.
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The TNM staging system defines T stage as representing“the extent of the primary tumor.” It might therefore be
reasonably assumed that lung cancers with a higher T stage
(more “advanced” cancers) would be bigger than those with
a lower stage. However, only T1 tumors are defined exclu-
sively by size (3.0 cm), whereas T2 to T4 tumors can be
any size, although one of the three T2 descriptors is “size
greater than 3 cm.” For the surgeon, involvement of critical
structures may be of more importance in determining resect-
ability than size. This is recognized by the T4 descriptors,
which allow tumors to be any size, but they are generally
unresectable because of involvement of adjacent structures.
However, for the radiation oncologist, size may be more
important than location, because for some cancers, tumor
volume is an important determinant of the likelihood of tumor
response.1 It is therefore paradoxical that T4 tumors, which
are the ones most likely to be treated with radiotherapy, are
not defined by size. Some retrospective studies have sug-
gested that in patients treated with radiotherapy for non-small
cell lung cancer (NSCLC), tumor size is indeed related to
survival.2–4 In contrast, we did not find an association be-
tween T stage and survival.5
The Trans-Tasman Radiation Oncology Group
(TROG) 99-05 is a prospective, multicenter, observational
study designed to test the hypothesis that tumor volume is an
independent prognostic factor in patients with NSCLC treated
by nonsurgical means. The rationale is that because tumor
size is not a consistent determinant of T stage, there may not
be a relationship between T stage and volume and, conse-
quently, none between T stage (or stage group) and survival.
Information on both tumor volume and maximum tumor
diameter are collected, as the volume may more accurately
reflect the total number of tumor clonogens.
We decided to use the TROG 99-05 database to exam-
ine the relationship between tumor volume and stage; if there
were a poor correlation, this would justify the collection of
information about size in addition to conventional stage. We
also decided to examine the relationship between tumor
diameter and tumor volume to determine whether diameter is
an adequate surrogate for volume.
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PATIENTS AND METHODS
To be eligible for TROG 99-05, patients had to meet
the following eligibility criteria:
1. Histologic or cytologic diagnosis of NSCLC.
2. Disease confined to primary site with or without in-
trathoracic lymph node involvement.
3. Computed tomography (CT) imaging of the thorax
performed as part of the radiotherapy planning proce-
dure.
4. The primary tumor and involved lymph nodes had been
contoured by a diagnostic radiologist.
5. Definitive management to consist of radical radiother-
apy with or without chemotherapy.
6. Primary tumor and involved lymph nodes are measur-
able.
The following criteria excluded patients from the study:
1. Evidence of metastatic disease (M1).
2. Prior treatment of this cancer.
3. Surgery planned as part of initial treatment.
Patients were registered at the time of radiotherapy
planning and before the commencement of treatment. The
tumor was contoured according to a standardized protocol6
and based on the outlines drawn by the radiologist (see
Appendix 2 for the full protocol). If patients were treated by
combined-modality therapy, contouring had to be performed
before the commencement of any form of treatment, includ-
ing, for example, induction chemotherapy. Consistency of
contouring between centers was checked by auditing the first
five contours from each site and random audit of one in 20
contours thereafter.
Procedures to stage patients were not standardized but
included, as a minimum, a contrast-enhanced CT scan of the
chest and upper abdomen. Bone scan and CT or magnetic
resonance imaging of the brain were performed if clinically
indicated. F-18 deoxyglucose positron emission tomography
(PET) scanning was used at a number of centers, and the PET
stage was documented separately from the CT stage. The
stage assigned in this study is based exclusively on CT
information.
Statistical Analysis
Variables analyzed were tumor volume (i.e., primary
tumor volume, in milliliters), maximum tumor diameter (i.e.,
from horizontal cross-sections of the primary tumor from CT
scans, in centimeters), total tumor volume (i.e., primary plus
nodal tumor volumes, in milliliters), clinical T stage, and
clinical stage. The derived variable, spherical tumor diameter
(S), of a tumor with volume V was defined as the diameter of
a spherical tumor with the same tumor volume:
S
3
6V ⁄
Tumor volumes and diameters were analyzed as their
logarithms: it is expected (and it was verified from data) that
measurement errors would be proportional to volumes and
diameters rather than be constant. Consequently, summary
measures are given in terms of geometric means and coeffi-
cients of variation (CVs), or percentage errors; also, means of
log data are interpreted as logs of geometric means and
standard deviations of log data as CVs of the original (un-
transformed) data.7
Spherical tumor diameter (S) is directly related to tumor
volume—if you know one, you know the other. Also, spher-
ical tumor diameter is more directly comparable to maximum
tumor diameter (M) and, thus, more readily interpretable than
is tumor volume. Therefore, assessment of the relationship
between tumor volume and maximum tumor diameter (M), in
plots and analyses, was undertaken by examining the rela-
tionship between spherical tumor diameter (S) and maximum
tumor diameter. The simplest model used to fit a relationship
between S and M (excluding the error term) is:
M kS (1)
That is, “on average,” the maximum tumor diameter is
a constant multiple of the spherical diameter, where the
constant multiple, k, would be expected to be greater than 1.
On taking logs, this translates into:
log (M) log (k) log (S) (2)
To allow for a departure from the strict constant mul-
tiple model, the latter model (Eq. 2) is most conveniently
modified to give:
log (M)log (S) (3)
where   logk and   1 indicates the simple
constant multiple case in Equations 1 and 2 above. In terms
of M and S, this model is equivalent to:
M kS (4)
Models were fit using simple linear regression. Pearson
correlation coefficients were calculated. Volumes were com-
pared between stage categories using one-way analysis of
variance. As an alternative way of assessing how well stage
is correlated with tumor volume, patients were cross-classi-
fied by stage and a grouping of volume for which there were
the same number of categories and the same number of
patients per category. The concordance rate is then the per-
centage of patients who occupy the same corresponding
categories for stage and volume. In each case, the concor-
dance has been associated with a correlation coefficient
obtained from simulation of bivariate normal data (with
known correlation) that have been cross-tabulated using the
relevant marginal frequencies.
RESULTS
Between September 7, 1999, and September 20, 2005,
434 patients were registered on this study, of whom 30 either
did not have volume data available or were ineligible. This
left 404 patients available for analysis. The baseline charac-
teristics of these patients are shown in Table 1.
D. L. Ball et al. Journal of Thoracic Oncology • Volume 1, Number 7, September 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer668
Tumor Volume versus Maximum Tumor
Diameter
Figure 1A shows maximum tumor diameter plotted
against spherical tumor diameter and Figure 1B shows the
same plot but on log scales. The correlation coefficient
between log maximum tumor diameter and log spherical
tumor diameter is 0.93 (p  0.001). The  parameter in the
above model (Eq. 4) is 1.041, just significantly different from
1 (p  0.044). Using the simple model (Eq. 2), however,
leads to the relationship:
M 1.21S (5)
with a CV approximately the line of 17%. That is, the
maximum tumor diameter can be estimated from the spheri-
cal tumor diameter by increasing the latter by 21%; and the
error of this estimate is 17% (i.e., 34% will encompass the
true maximum tumor diameter in approximately 95% of
cases). Prediction is not greatly improved by incorporating
the  parameter and the above model (Eq. 5) is far simpler.
Conclusions were little affected by excluding three possible
outliers, all with a maximum diameter much smaller than the
spherical diameter.
Tumor Volume versus Clinical T Stage
Table 2 summarizes tumor volume for each clinical
T-stage group. There is a highly significant trend for increas-
ing volume with increasing T stage (p  0.001). However,
examination of individual volumes plotted against clinical T
stage (Figure 2) reveals that some of the smallest T3 and T4
tumors are smaller than the largest T1 tumors. If there were
a direct relationship between T stage and volume, there
should be a consistent increase in volume with T stage. To
TABLE 1. Baseline Characteristics
Factor Median Range No. %
All 404 100
Sex
Male 280 69
Female 124 31
Cell type
Squamous 185 46
Adenocarcinoma 100 25
Large cell 76 19
Mixed 5 1
Unspecified 33 8
Other 5 1
T stage (clinical)
1 49 12
2 193 48
3 83 21
4 79 20
N stage (clinical)
0 208 51
1 22 5
2 136 34
3 38 9
Clinical stage
1a 37 9
1b 95 24
2a 2 0.5
2b 44 11
3a 113 28
3b 113 28
Clinical stage
1 132 33
2 46 11
3 226 56
Atelectasis present?
No 313 77
Yes 91 23
Satellite nodules present? No 390 97
Yes 14 3
Age (yr) 70 40–89
Spherical tumor diameter (cm) 4.5 1.1–16.3
Maximum tumor diameter (cm) 5.6 1–19
Tumor volume (ml) 48 0.7–2250
Nodal volume (ml) (n  185)* 12.5 0–270
Total tumor volume (ml) 64 1.4–2250
*Of 196 node-positive patients, five are coded as having zero nodal volume (nodes
 1 cm diameter) and 11 as missing (inability to distinguish primary from nodal tumor).
FIGURE 1. Maximum tumor diameter versus tumor volume
using (A) untransformed scales and (B) log10 scales. The dot-
ted lines indicate the 45-degree lines (tumor volume is repre-
sented by its spherical tumor diameter).
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explore this, in Table 3, the T-stage classification is compared
with a grouping of tumor volume (see above under Statistical
Analysis). The concordance rate is only 55%, which corre-
sponds to a correlation coefficient for continuous data of 0.72.
Total Tumor Volume versus Stage Group
Table 4 summarizes total volume (primary tumor plus
volume of all nodes whose maximum diameter is equal to or
exceeds 1 cm) versus clinical stage group. Again, there is a
highly significant trend for increasing volume with increasing
stage group (p  0.001). Individual data are shown in Figure
3, which reveals that many of the largest stage 1 tumors are
bigger than the smallest stage 3 tumors. Table 5 shows the
clinical stage classification compared with a conformed clas-
sification of total volume (see above under Statistical Anal-
ysis). The concordance rate indicates that, in 67% of patients,
the category based on total tumor volume is the same as that
based on clinical stage (this rate corresponds to a correlation
coefficient for continuous data of 0.71).
DISCUSSION
The results of this study support the rationale for TROG
99-05, confirming that there is limited correlation between T
stage or stage group and tumor volume in patients with
NSCLC. Because the current TNM system takes little ac-
count of tumor size, this finding should not be surprising.
Although the limited correlation between stage group and
volume has been observed by others,8–10 this issue and its
implications for the nonsurgical population have received
TABLE 2. Tumor Volume versus Clinical T Stage
Clinical
T Stage
No. of
Patients
Geometric Mean
Volume (ml) % CV Median Range
1 49 5 73 6 1–21
2 193 40 90 37 5–1030
3 83 84 93 79 5–590
4 79 101 93 109 3–2300
All 404 44 125 48 1–2300
*p overall (3 df)  0.001; p trend  0.001.
FIGURE 2. Tumor volume (log10 scale) versus clinical T
stage. Median values are denoted by the vertical lines.
TABLE 3. T-Stage Classification versus Volume-Based
Classification with Same Numbers of Patients in Successive
Categories*
Clinical T Stage
Tumor Volume Category 1 2 3 4
0, 9.4 38 8 2 1 49
9.4, 67.5 11 128 31 23 193
67.5, 130 38 23 22 83
 130 19 27 33 79
All 49 193 83 79 404
*Concordance analysis gives the following values for the difference between
categories: 0, n 222 (55%); 1, n 137 (34%); 2, n 44 (11%); and 3, n 1 (0.2%).
TABLE 4. Total Tumor Volume (Primary plus Nodes) versus
Clinical Stage Group*
Clinical
Stage
No. of
Patients
Geometric Mean
Volume (ml) % CV Median Range
1 132 20 114 20 1–240
2 46 65 96 68 5–590
3 226 93 84 96 7–2300
All 404 54 119 64 1–2300
*p overall (2 df)  0.001; p trend  0.001.
FIGURE 3. Total (primary plus node) tumor volume (log10
scale) versus clinical stage. Median values are denoted by
the vertical lines. .
TABLE 5. Stage Group Classification versus Volume-Based
Classification with Same Numbers of Patients in Successive
Categories
Clinical Stage
Total Tumor Volume (ml) 1 2 3
0, 37.3 92 12 28 132
37.3, 52 11 8 27 46
 52 29 26 171 226
All 132 46 226 404
*Concordance analysis gives the following values for the difference between
categories: 0, n  271 (67%); 1, n  76 (19%); and 2, n  57 (14%).
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little attention previously. However, the message is clear:
stage cannot reliably be taken to give an indication of the
volume of disease. If tumor volume is a determinant of
radiation response in NSCLC, as it appears to be for some
other histologies, then stage (particularly T stage) may be of
limited prognostic value in patients with NSCLC who are
treated by nonsurgical means, as suggested by our own
retrospective study.5 If size is prognostically important, it will
be necessary to document it in addition to stage. We have
demonstrated that there is good correlation between measured
maximum diameter and tumor volume. Therefore, it may be
sufficient to document diameter without going to the addi-
tional effort required to calculate volume.
CONCLUSIONS
TROG 99-05 continues to accrue, with a target of 500
assessable patients. The prognostic value of both diameter
and volume will be examined to see whether volume provides
additional information not available from diameter alone.
Based on this preliminary analysis, it seems unlikely that it
will. We have, however, established that there is sufficient
justification for pursuing the investigation of tumor size as a
potential prognostic factor independent of stage in patients
with NSCLC who are treated by nonsurgical means.
APPENDIX 1
The following participants and institutions contributed
to the study: G. Duchesne and B. Matheson (Alfred Hospital);
T. Hemanth, H. Krawitz, and A. Macann (Auckland Hospi-
tal); M. Feigen, G. Quong, and M. Wada (Austin-Repatria-
tion Medical Centre); D. Christie (East Coast Cancer Centre);
G. Delaney, D. Forstner, and S. Vinod (Liverpool Hospital);
C. Hamilton, P. O’Brien, and C. Wratten (Newcastle Mater
Hospital); D. Ball, P. Bowden, I. D’Costa, M. Lim Joon, M.
Mac Manus, G. Wheeler, and A. Wirth (Peter MacCallum
Cancer Centre); B. Burmeister, B. Hickey, and M. Lehman
(Princess Alexandra Hospital); G. Bryant, B. Burmeister, B.
Hickey, M. Poulsen, and J. Ramsay (Queensland Radium
Institute–Mater); M. Borg, S. Carruthers, M. Penniment, D.
Roos, and E. Yeoh (Royal Adelaide Hospital); M. Tin (Royal
Prince Alfred Hospital); D. Joseph and N. Spry (Sir Charles
Gairdner Hospital); P. Graham (St. George Hospital); and R.
Alvandi (Westmead Hospital).
APPENDIX 2. PROCEDURE FOR THE
MEASUREMENT OF THE VOLUME OF THE
PRIMARY TUMOR AND INVOLVED
LYMPH NODES
A. Preparation
Y Volume measurements will be based on planning CT
images, which may or may not be contrast-enhanced.
Y The interval between images should be no greater
than 1 cm.
Y If the planning image does not have contrast, a recent
(within 4 weeks of planning) diagnostic contrast-en-
hanced scan should be available for viewing, alongside
the planning scan.
Y The planning CT scan should include all the known
tumor and all enlarged intrathoracic lymph nodes.
Y The computer planning system must have software ca-
pable of calculating the volume of contoured structures.
Y If available, PET scans may be used to help clarify
tumor boundaries. The case record forms will capture
data regarding whether or not PET was used as an aid,
and if it was, whether the tumor volume changed as a
result.
B. Steps
1. Identification of Tumor and Nodes
The purpose of the exercise is to measure the volume of
visible macroscopic disease, not to contour a clinical target
volume. The contour should therefore closely hug the surface
of the tumor and should not include a margin for suspected or
microscopic spread. Opacities that are thought to be unlikely
to represent tumor, but which a prudent radiation oncologist
might include in the clinical tumor volume because of lack of
absolute certainty, should be excluded. The tumor, and all
hilar and mediastinal nodes with a diameter greater than 1
cm, should be identified and outlined with a fine-tip felt pen
by a diagnostic radiologist on hard copy.
2. Contour Using Mediastinal Window
Initially, the volume is contoured using mediastinal
window settings: width  400 HU, level  20 HU. Be-
cause the density scale on commercial planning systems does
not always correspond with Hounsfield units, it is recom-
mended that the window settings be standardized for each
individual department and that the same settings be used on
every occasion. It is suggested that a diagnostic radiology
technician be asked to establish which settings most closely
correspond with the range of Hounsfield units for both me-
diastinal and lung windows as described in the article by
Harris et al.11 For disease involving the mediastinum, the
tumor/node edge will be defined by the interface between
tumor/node and fat or contrast-enhanced vessel using medi-
astinal window settings.
3. Using Lung Window
Y In practice, it is easiest to determine the tumor volume
using the mediastinal settings and then to enlarge this
volume as required after changing to the lung settings.
The lung window should most closely correspond with a
level of –750 HU and a window width of 850 HU. With
these settings, the volume can only be contoured at the
lung/tumor interface, because all mediastinal definition
is lost.
Y The maximum cross-sectional dimension of the tumor
should be measured and recorded using the lung window
image.
C. Special Situations
1. Spicules
For the purposes of this exercise, only the solid portion
of the tumor should be contoured. Fine spicules radiating into
the surrounding lung are not included, as interpretation of
Journal of Thoracic Oncology • Volume 1, Number 7, September 2006 Stage as an Indicator of Tumor Volume in NSCLC
Copyright © 2006 by the International Association for the Study of Lung Cancer 671
their size and significance varies considerably between
observers.
2. Cavitating Tumor
If the tumor is cavitating, its volume will be taken to be
that volume if no cavitation were present.
3. Atelectasis
Patients with adjoining atelectasis represent a special
case. Sometimes, the radiologist is able to distinguish atelec-
tatic lung from tumor, especially if liver window settings are
used (width  150 HU, level  50 HU). These patients are
eligible for the study if the radiologist is confident about the
margins of the tumor. Where it is not possible to distinguish
atelectatic lung and tumor, the patient will be ineligible for
the study.
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